Equillium Inc EQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.96
- Day Range
- $2.81–3.04
- 52-Week Range
- $0.33–3.54
- Bid/Ask
- $2.80 / $3.00
- Shares Outstanding
- 63.23M
- Market Cap
- $183.99M
- Volume/Avg
- 2M / 786,194
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 14
- Website
- https://www.equilliumbio.com
Valuation
|
Metric
|
EQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.35 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EQ
|
|---|---|
Quick Ratio | 18.33 |
Current Ratio | 18.62 |
Interest Coverage | — |
Quick Ratio
EQ
Profitability
|
Metric
|
EQ
|
|---|---|
Return on Assets (Normalized) | −53.09% |
Return on Equity (Normalized) | −62.54% |
Return on Invested Capital (Normalized) | −64.83% |
Return on Assets
EQ
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|J%H?@Qh | LOCK|c%j$^ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|N$#vSt | LOCK|JWztG | $70B | |||
| argenx SE ADR
ARGX
| LOCK|SHh&y% | LOCK|XZ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|nF!w?qP | LOCK|t#Rg^ | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^K&b$qT | LOCK|>F | $36B | |||
| Moderna Inc
MRNA
| LOCK|pr#zX>m | LOCK|r& | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|qnVt$L< | LOCK|Z$>C | $25B | |||
| Incyte Corp
INCY
| LOCK|^c@lfQ | LOCK|#@d | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|$&%LrW> | LOCK|@@ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&hMXwp | LOCK|@L | $17B |
United States